417 related articles for article (PubMed ID: 16900553)
21. Design and analysis of prostate cancer trials.
Sylvester R
Acta Urol Belg; 1994 Apr; 62(1):23-9. PubMed ID: 8197926
[TBL] [Abstract][Full Text] [Related]
22. Estimation in flexible two stage designs.
Brannath W; König F; Bauer P
Stat Med; 2006 Oct; 25(19):3366-81. PubMed ID: 16220489
[TBL] [Abstract][Full Text] [Related]
23. Adaptive designs for confirmatory clinical trials.
Bretz F; Koenig F; Brannath W; Glimm E; Posch M
Stat Med; 2009 Apr; 28(8):1181-217. PubMed ID: 19206095
[TBL] [Abstract][Full Text] [Related]
24. Alternative trial design in amyotrophic lateral sclerosis saves time and patients.
Groeneveld GJ; Graf M; van der Tweel I; van den Berg LH; Ludolph AC
Amyotroph Lateral Scler; 2007 Oct; 8(5):266-9. PubMed ID: 17852016
[TBL] [Abstract][Full Text] [Related]
25. Assessment of futility in clinical trials.
Snapinn S; Chen MG; Jiang Q; Koutsoukos T
Pharm Stat; 2006; 5(4):273-81. PubMed ID: 17128426
[TBL] [Abstract][Full Text] [Related]
26. Adaptive trial design: a general methodology for censored time to event data.
Jahn-Eimermacher A; Ingel K
Contemp Clin Trials; 2009 Mar; 30(2):171-7. PubMed ID: 19130902
[TBL] [Abstract][Full Text] [Related]
27. Adaptive statistical analysis following sample size modification based on interim review of effect size.
Hung HM; Cui L; Wang SJ; Lawrence J
J Biopharm Stat; 2005; 15(4):693-706. PubMed ID: 16022173
[TBL] [Abstract][Full Text] [Related]
28. Sequential designs for clinical trials in amyotrophic lateral sclerosis.
Groeneveld GJ; van der Tweel I; Wokke JH; van den Berg LH
Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Dec; 5(4):202-7. PubMed ID: 15799547
[TBL] [Abstract][Full Text] [Related]
29. Efficient group sequential designs when there are several effect sizes under consideration.
Jennison C; Turnbull BW
Stat Med; 2006 Mar; 25(6):917-32. PubMed ID: 16220524
[TBL] [Abstract][Full Text] [Related]
30. Group sequential t-test for clinical trials with small sample sizes across stages.
Shao J; Feng H
Contemp Clin Trials; 2007 Sep; 28(5):563-71. PubMed ID: 17434814
[TBL] [Abstract][Full Text] [Related]
31. Adaptive designs at European Organisation for Research and Treatment of Cancer (EORTC) with a focus on adaptive sample size re-estimation based on interim-effect size.
Mauer M; Collette L; Bogaerts J;
Eur J Cancer; 2012 Jun; 48(9):1386-91. PubMed ID: 22281098
[TBL] [Abstract][Full Text] [Related]
32. Increasing the sample size at interim for a two-sample experiment without Type I error inflation.
Dunnigan K; King DW
Pharm Stat; 2010; 9(4):280-7. PubMed ID: 19764040
[TBL] [Abstract][Full Text] [Related]
33. Mid-course sample size modification in clinical trials based on the observed treatment effect.
Jennison C; Turnbull BW
Stat Med; 2003 Mar; 22(6):971-93. PubMed ID: 12627413
[TBL] [Abstract][Full Text] [Related]
34. Sample size re-estimation for survival data in clinical trials with an adaptive design.
Togo K; Iwasaki M
Pharm Stat; 2011; 10(4):325-31. PubMed ID: 22328325
[TBL] [Abstract][Full Text] [Related]
35. Optimal spending functions for asymmetric group sequential designs.
Anderson KM
Biom J; 2007 Jun; 49(3):337-45. PubMed ID: 17623339
[TBL] [Abstract][Full Text] [Related]
36. Optimization of adaptive designs: efficiency evaluation.
Menon S; Chang M
J Biopharm Stat; 2012; 22(4):641-61. PubMed ID: 22651106
[TBL] [Abstract][Full Text] [Related]
37. Sample size for two-stage studies with maintenance therapy.
Feng W; Wahed AS
Stat Med; 2009 Jul; 28(15):2028-41. PubMed ID: 19382105
[TBL] [Abstract][Full Text] [Related]
38. Interim futility analysis with intermediate endpoints.
Goldman B; LeBlanc M; Crowley J
Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
[TBL] [Abstract][Full Text] [Related]
39. Efficient ways exist to obtain the optimal sample size in clinical trials in rare diseases.
van der Lee JH; Wesseling J; Tanck MW; Offringa M
J Clin Epidemiol; 2008 Apr; 61(4):324-30. PubMed ID: 18313556
[TBL] [Abstract][Full Text] [Related]
40. A general statistical principle for changing a design any time during the course of a trial.
Müller HH; Schäfer H
Stat Med; 2004 Aug; 23(16):2497-508. PubMed ID: 15287080
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
